The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD

References

• DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax20025784785212324669
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 Pt 1141814229603117
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoAEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med20103631128113820843247
   PubMed Web of Science ®Google Scholar
• JenkinsCRJonesPWCalverleyPMEfficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyRespir Res2009105919566934
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med200735677578917314337
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJTRial of Inhaled STeroids ANd long-acting beta2 agonists study groupCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
• SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J2003211748112570112
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management and Prevention of Chronic Pulmonary Obstructive DiseaseGlobal Initiative for Chronic Obstructive Lung Disease updated 2014. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jan23.pdfAccessed January 24, 2014
   Google Scholar
• SeemungalTADonaldsonGCBhowmikAJeffriesDJWedzichaJATime course and recovery of exacerbations in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200016151608161310806163
   PubMed Web of Science ®Google Scholar
• SinDDManSFMarciniukDDABC (Advair, Biomarkers in COPD) InvestigatorsThe effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2008177111207121418310480
   PubMed Web of Science ®Google Scholar
• SinDDMillerBEDuvoixAECLIPSE InvestigatorsSerum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201118391187119221216880
   PubMed Web of Science ®Google Scholar
• EXACT-PROInitiativeThe Exacerbations of Chronic Pulmonary Disease Tool (EXACT) User Manual Version 5BethesdaEvidera2013
   Google Scholar
• JonesPWLamarcaRChuecosFCharacterisation and impact of reported and unreported exacerbations: results from ATTAINEur Respir J20144451156116525234803
   PubMed Web of Science ®Google Scholar
• LimWSBaudouinSVGeorgeRCPneumonia Guidelines Committee of the BTS Standards of Care CommitteeBTS guidelines for the management of community acquired pneumonia in adults: update 2009Thorax200964Suppl 3iii1iii5519783532
   PubMed Web of Science ®Google Scholar
• TashkinDPRennardSIMartinPEfficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trialDrugs200868141975200018778120
   PubMed Web of Science ®Google Scholar
• RennardSITashkinDPMcElhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956519368417
   PubMed Web of Science ®Google Scholar
• DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsLancet Respir Med20131321022324429127
   PubMed Web of Science ®Google Scholar
• AnzuetoAFergusonGTFeldmanGEffect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomesCOPD20096532032919863361
   PubMedGoogle Scholar
• FergusonGTAnzuetoAFeiREmmettAKnobilKKalbergCEffect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbationsRespir Med200810281099110818614347
   PubMed Web of Science ®Google Scholar
• RossiAKristufekPLevineBEFormoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPDChest200212141058106911948033
   PubMed Web of Science ®Google Scholar
• DahlRGreefhorstLANowakDFormoterol in Chronic Obstructive Pulmonary Disease I Study GroupInhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001164577878411549532
   PubMed Web of Science ®Google Scholar
• BatemanEDBleeckerERLötvallJDose effect of once-daily fluticasone furoate in persistent asthma: a randomized trialRespir Med2012106564265022342538
   PubMed Web of Science ®Google Scholar
• JaradNAWedzichaJABurgePSCalverleyPMAn observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study GroupRespir Med199993316116610464871
   PubMed Web of Science ®Google Scholar
• LapperreTSSnoeck-StrobandJBGosmanMMGroningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study GroupEffect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2009151851752719841453
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWISDOM InvestigatorsWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med20143711285129425196117
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyGuideline on Clinical Development of Fixed Dose Combination Medicinal Products EMA/CHMP/281825/2015LondonEuropean Medicines Agency2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/05/WC500186840.pdfAccessed July 16, 2015
   Google Scholar
• ICH Harmonised Tripartite Guideline: Choice of Control Group and Related Issues in Clinical Trials.E10ICH2000 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdfAccessed July 16, 2015
   Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAINSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• van der PalenJKleinJJvan HerwaardenCLZielhuisGASeydelERMultiple inhalers confuse asthma patientsEur Respir J19991451034103710596686
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTPOET-COPD InvestigatorsTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med20113641093110321428765
   PubMed Web of Science ®Google Scholar
• LangsetmoLPlattRWErnstPBourbeauJUnderreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohortAm J Respir Crit Care Med2008177439640118048806
   PubMed Web of Science ®Google Scholar
• SinDDLeungRGanWQManSPCirculating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot studyBMC Pulm Med200771317922919
   PubMedGoogle Scholar
• LomasDASilvermanEKEdwardsLDEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigatorsSerum surfactant protein D is steroid sensitive and associated with exacerbations of COPDEur Respir J20093419510219164344
   PubMed Web of Science ®Google Scholar
• ShakooriTASinDDGhafoorFBashirSBokhariSNSerum surfactant protein D during acute exacerbations of chronic obstructive pulmonary diseaseDis Markers200927628729420075511
   PubMed Web of Science ®Google Scholar
• DickensJAMillerBEEdwardsLDSilvermanEKLomasDATal-SingerREvaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigatorsCOPD association and repeatability of blood biomarkers in the ECLIPSE cohortRespir Res20111214622054035
   PubMed Web of Science ®Google Scholar
• DuvoixADickensJHaqIBlood fibrinogen as a biomarker of chronic obstructive pulmonary diseaseThorax201368767067622744884
   PubMed Web of Science ®Google Scholar
• PascoeSLocantoreNDransfieldMTBarnesNCPavordIDBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsLancet Respir Med20153643544225878028
   PubMed Web of Science ®Google Scholar
• PapaioannouAIBartziokasKLoukidesSCardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk?Eur Respir J201546384684925882807
   PubMed Web of Science ®Google Scholar
• DivoMCoteCde TorresJPBODE Collaborative GroupComorbidities and risk of mortality in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2012186215516122561964
   PubMed Web of Science ®Google Scholar
• HuiartLErnstPSuissaSCardiovascular morbidity and mortality in COPDChest200512842640264616236937
   PubMed Web of Science ®Google Scholar
• LahousseLNiemeijerMNvan den BergMEChronic obstructive pulmonary disease and sudden cardiac death: the Rotterdam studyEur Heart J201536271754176125920404
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBTORCH InvestigatorsCardiovascular events in patients with COPD: TORCH study resultsThorax201065871972520685748
   PubMed Web of Science ®Google Scholar
• CrimCCalverleyPMAndersonJAPneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study resultsEur Respir J200934364164719443528
   PubMed Web of Science ®Google Scholar
• CalverleyPMStockleyRASeemungalTAInvestigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) InvestigatorsReported pneumonia in patients with COPD: findings from the INSPIRE studyChest2011139350551220576732
   PubMed Web of Science ®Google Scholar
• WedzichaJASinghDVestboJFORWARD InvestigatorsExtrafine beclomethasone/formoterol in severe COPD patients with history of exacerbationsRespir Med201410881153116224953015
   PubMed Web of Science ®Google Scholar
• KewKMSeniukovichAInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20143CD01011524615270
   PubMed Web of Science ®Google Scholar
• FesticEScanlonPDIncident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?Am J Respir Crit Care Med2015191214114825409118
   PubMed Web of Science ®Google Scholar